IP Library Granted Patent US 10,576,155
Granted Patent B2
US 10,576,155 · App. 15/591,818 · Granted Mar 3, 2020

Low molecular weight cationic lipids for oligonucleotide delivery

Inventors: Matthew G. Stanton (Marlton, NJ); Brian W. Budzik (Perkiomenville, PA); Gregory L. Beutner (Green Brook, NJ); Hongbiao Liao (Bridgewater, NJ)
Assignee: SIRNA THEREAPEUTICS, INC.
A61K47/18C07C211/04C07C211/08C07C211/17C07C211/21C07D207/06C12N15/88A61K45/00A61K48/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,576,155
App. No.
15/591,818
Granted
Mar 3, 2020
Kind
B2
Abstract

The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Claims (21)

1. A cationic lipid of Formula A:

wherein:

R 1 and R 2 are independently selected from (C 1 -C 6 )alkyl, or R 1 and R 2 can be taken together with the nitrogen to which they are attached to form a pyrrolidine ring;

R 3 is H;

n is 0, 1, 2, 3, 4 or 5;

L 1 is selected from straight chain C 12 -C 24 alkenyl;

or alkyl selected from the following structure;

and

L 2 is selected from C 3 -C 9 alkyl and C 3 -C 9 alkenyl;

or any pharmaceutically acceptable salt or stereoisomer thereof.

2. A cationic lipid which is selected from:

(12Z, 15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (Compound 31);

N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine (Compound 40)

or any pharmaceutically acceptable salt or stereoisomer thereof.

3. A lipid nanoparticle comprising a cationic lipid of claim 1 .

4. The lipid nanoparticle of claim 3 , wherein the lipid nanoparticle further comprises, cholesterol, DSPC and PEG-DMG.

5. The lipid nanoparticle of claim 3 , wherein the lipid nanoparticle further comprises an oligonucleotide.

6. The lipid nanoparticle of claim 5 , wherein the oligonucleotide is siRNA.

7. A cationic lipid which is:

N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine (Compound 40); or any pharmaceutically acceptable salt or stereoisomer thereof.

8. A lipid nanoparticle comprising cationic lipid N,N-dimethyl-3-{7-[(1S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine (Compound 40), cholesterol, DSPC and PEG-DMG.

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2017
From: STANTON, MATTHEW G.; BUDZIK, BRIAN W.; BEUTNER, GREGORY L.; LIAO, HONGBIAO
To: MERCK SHARP & DOHME CORP.
Reel/Frame 042382/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2017
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 042382/0207 →
Continuity (4)
Continuation 13823830
Provisional Application 61514270 · Aug 2, 2011
Provisional Application 61384486 · Sep 20, 2010
Related Publication 20180000939A1 · Jan 4, 2018